Table 1.
Clinicopathological characterization of each patient.
| Aggressiveness | Patient ID | Sex | Age (yr) | Tumor Size (cm) | Fuhrman Grade | Invasion (Perinephric/Sinus Fat/Vascular) | Survival Time a (m) | Outcome b | Recurrence Site | Synchronous Metastatic Site |
|---|---|---|---|---|---|---|---|---|---|---|
| N | Pt0-1 | M | 67 | 1.6 | 3 | N | 41 | ned | ||
| N | Pt0-2 | M | 56 | 6.3 | 3 | Y | 36 | ned | ||
| N | Pt0-3 | M | 76 | 3.5 | 2 | Y | 32 | ned | ||
| N | Pt0-4 | F | 73 | 5.3 | 2 | Y | 92 | ned | ||
| N | Pt0-5 | M | 81 | 6.6 | 3 | Y | 17 | ned | ||
| N | Pt0-6 | M | 72 | 5.4 | 3 | Y | 77 | ned | ||
| N | Pt0-7 | M | 60 | 6.9 | 3 | Y | 59 | ned | ||
| N | Pt0-8 | M | 59 | 6.4 | 3 | Y | 63 | ned | ||
| N | Pt0-9 | M | 61 | 4.7 | 3 | Y | 58 | ned | ||
| N | Pt0-10 | M | 76 | 5.0 | 2 | N | 46 | ned | ||
| N | Pt0-11 | M | 65 | 4.4 | 2 | N | 32 | ned | ||
| N | Pt0-12 | M | 75 | 2.7 | 2 | N | 34 | ned | ||
| Y | Pt1-1 | M | 73 | 5.5 | 3 | N | 19 | cd | Lung | |
| Y | Pt1-2 | M | 73 | 6.9 | 4 | Y | 17 | cd | Lung | |
| Y | Pt1-3 | M | 60 | 5.1 | 3 | Y | 57 | pd/cd | Local recurrence, liver | |
| Y | Pt1-4 | M | 58 | 2.8 | 3 | N | 36 | cd | Bone | |
| Y | Pt1-5 | M | 74 | 1.6 | 2 | N | 48 | pd/cd | Lung, lymph nodes | |
| Y | Pt1-6 | M | 70 | 6.6 | 3 | Y | 38 | pd/cd | Liver, bone, lymph nodes | |
| Y | Pt1-7 | M | 61 | 6.7 | 3 | Y | 14 | pd/cd | Lung, liver | Lung, bone |
| Y | Pt1-8 | M | 54 | 4.8 | 2 | Y | 56 | pd/cd | Local recurrence | |
| Y | Pt1-9 | M | 66 | 4.2 | 2 | N | 20 | ned | Bone | |
| Y | Pt1-10 | M | 60 | 5.2 | 4 | Y | 78 | pd | Lung, bone | |
| Y | Pt1-11 | M | 70 | 3.5 | 2 | N | 58 | pd | Bone | |
| Y | Pt1-12 | M | 44 | 5.5 | 3 | Y | 31 | ned | Lung |
a Survival time was defined as the time from nephrectomy until the patient’s death or the last time that the patient was known to be alive; b cd, cancer death; ned, no evidence of disease; pd, progression of the disease.